Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)

Market Cap	4.48B +16.7%
Revenue (ttm)	1.78B +1.1%
Net Income	61.07M +98.3%
EPS	0.11 +97.9%
Shares Out	552.92M
PE Ratio	73.66
Forward PE	n/a
Dividend	0.01 (0.17%)
Ex-Dividend Date	Jan 9, 2026

Volume	29,110,490
Open	8.30
Previous Close	8.10
Day's Range	8.08 - 8.39
52-Week Range	6.13 - 9.44
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:600222

Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the manufacture and sale of pharmaceutical preparations and Chinese herbal medicine slices in China. The company offers Shuanghuanglian oral liquid series, Shuangjinlian mixture, children's heat-clearing and cough-relieving oral liquid series, pediatric antipyretic oral liquid, Jiaweishanxiang Zhengqi compound preparation, honeysuckle dew, danshen oral liquid, Shengmai Yin, pediatric compound chicken gizzard chewable tablets, Chewable tablets, huperzine A tablets, Wuzi Yanzong oral liquid, co...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,084
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600222

Financial Performance

In 2025, SHA:600222's revenue was 1.76 billion, a decrease of -9.46% compared to the previous year's 1.94 billion. Earnings were 60.00 million, an increase of 18.74%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 20, 2026

Data Sources Report a data error